Ontario teams collaborate to discover
first-in-class drug for blood cancers
Tackling cancer is tough business. No matter how large and successful a single laboratory may be, developing cancer therapeutics is rarely done by a single investigator. OICR was created to bring together strengths within the province of Ontario and forge new and exciting collaborations to translate research into patient impact. Recently, Ontario researchers identified a weakness in leukemia, and while challenging, this target became a focus for OICR and its partners. This is the story of a first-in-class inhibitor for the protein WDR5, discovered and developed in Ontario – and the translational path it has taken toward commercialization.
Finding the ‘chemical hook’ for the gene MLL-1
MLL-1 is a gene well-known to play a role in driving the growth of many types of cancer. In particular, malfunction of MLL-1 has been identified as an important factor in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). There are still large unmet patient needs in these cancers that warrant additional research.
Over the last several years, OICR’s Drug Discovery group (OICR DD) has been working with researchers from the Structural Genomics Consortium (SGC) at the University of Toronto to develop a chemical inhibitor that disables MLL-1 in a novel and ingenious way by specifically targeting WDR5, a scaffolding protein within the MLL-1 protein complex.
Given that WDR5 is a linchpin in this complex, the OICR-SGC team discovered that disrupting the MLL-1/WDR5 interaction with a drug-like compound provided a novel and efficient way to turn off MLL-1 and halt its ability to drive cancer.
“The method we have developed has the advantage of targeting a scaffolding protein that we hope will be more difficult for the cancer to mutate, reducing resistance and relapse. This will hopefully provide longer lasting remissions,” says Dr. Rima Al-awar, one of the leaders of the project and Director and Senior Principal Investigator, OICR DD. Additionally, by specifically targeting WDR5 the group has been able to optimize selectivity as opposed to targeting the MLL-1 complex itself, which has several close family members.
The WDR5 project began at SGC, a close collaborator of OICR DD that is also located in the MaRS Centre in Toronto. The team at SGC, led by Dr, Cheryl Arrowsmith, Chief Scientist, identified WDR5 as a potential target for disabling the activity of MLL-1. The group brought their findings to OICR DD, to further investigate WDR5 together and assess the potential for targeting the protein complex with drug-like molecules.
Dr. Aled Edwards, SGC’s Director, says that while the initial discovery of WDR5’s potential was exciting, it was difficult to see a clear path to move the project forward until they had what he calls a ‘chemical hook’, which in this case was a compound that could bind and block WDR5. “The group at OICR had done a lot of hard work in aggregating compound libraries that we then used together to try and find an inroad to making the chemistry work,” explains Edwards. “When we found a compound that fit WDR5, it was the inflection point, and things suddenly went from impossible to possible.”
Collaboratively building the path to commercialization
Moving innovative treatments into the clinic requires more than just great science. It also depends on having a strong commercialization strategy that can attract the necessary partners and investors to help research projects along the long road of development.
Early in the development of the WDR5 project, OICR DD partnered with FACIT to create a commercialization strategy and secure resources to bring their new innovation to the clinic. FACIT provided the necessary business, industry and management expertise as well as seed capital and start-up resources to support and accelerate the project. The early integration of FACIT and OICR’s expertise allowed them to develop the WDR5 inhibitor with a viable commercialization approach – a challenging feat for any laboratory. OICR DD leadership was essential in bringing extensive industry experience and perspectives to move this discovery towards the clinic.
“This partnership allows us to better position our projects to advance them into development, which is essential to the process of getting discoveries from bench to bedside,” says Al-awar. Together, OICR, FACIT and their differentiated approach to commercialization ensured the WDR5 project had the best chance to make an impact.
“Translating cancer breakthroughs requires many skill sets, from basic research to clinical and industrial expertise,” says Dr. David O’Neill, President, FACIT. “The OICR-FACIT model pulls these strengths together to maximize the benefits of Ontario’s innovations in the province. OICR’s collaboration with SGC provided a great foundation for the WDR5 project and we will seek the same strong commitment from industry partners to accelerate this program to patients.
Generating value from open collaborations
WDR5 was a unique asset from a commercialization perspective because it began in 2014 as an open drug discovery project. As with many open science projects, data were shared with the scientific community, including the structure of an initial WDR5 chemical probe. Conducting research in an open manner allowed the team to tap into a vast international network of experts, especially those that were able to test and demonstrate the efficacy of the WDR5 probe in cells. “Open science projects have to deal with less red tape, and fewer costs and legal issues that can sometimes slow down other projects,” explains Edwards.
Often, open science initiatives and traditional drug discovery initiatives, which have proprietary intellectual property, have different business models and use incompatible approaches to commercialization. The WDR5 project showed these approaches can be compatible, and the unique collaboration produced a chemical probe that was shared with the global academic community, which led to a better understanding of leukemia biology and therapeutic strategies.
Open science projects have to deal with less red tape, and fewer costs and legal issues that can sometimes slow down other projects. - Dr. Aled Edwards
OICR scientists were able to refine the chemical probe into an improved drug-like compound, which can now be tested in clinical trials. In drug discovery, having a strong way to protect the market for a molecule is a necessary step to attract clinical trial support from industry partners and ensure economic return on innovative research. Hence, coming up with a candidate drug and advancing leukemia biology is a great success of the many scientists associated with the OICR-SGC collaboration.
To attract the necessary investment to move our work toward a drug that can be used in the clinic, we took the open data and carved out something new and unique. By tapping into FACIT, we were able to visualize the commercial potential of the asset. - Dr Rima Al-awar
Al-awar recognizes that although open drug development has its advantages, it can sometimes bring challenges. “In order to attract the necessary investment and partners to move our work toward a drug that can be used in the clinic, we took the open data and carved out something new and unique. By tapping into FACIT, we were able to visualize the commercial potential of the asset, and subsequently create and protect intellectual property (IP). FACIT has been an invaluable partner.”
A differentiated strategic partnership
Other challenges that come with commercializing oncology research include sustaining long development times, finding the right fit with investors and partners, securing seed funding at an early stage, and competing with established players in the biotech field. The unique strategic partnership between OICR and FACIT has been established to address these challenges and commercialize Ontario’s best oncology innovations.
“The WDR5 project and the value of this IP reflects the close-knit relationship of discovery and commercialization. In recognizing they had the expertise to accelerate and develop a potential first-in-class, druggable version of the probe, OICR Drug Discovery flagged this opportunity to FACIT,” says O’Neill.
Once the potential of WDR5 was realized, FACIT quickly provided tools and services to move the project along, including the establishment of a start-up company called Propellon Therapeutics and providing Propellon with interim management and invested seed capital.
“FACIT’s resources and funding ensured Propellon moved to the next stage of development and growth in Ontario,” says O’Neill. “The seed investment allowed the start-up to maintain momentum and begin to identify strategic partners in the pharmaceutical industry and additional investors most committed to development in the province.” Currently, FACIT is actively exploring corporate development opportunities for the program.
The story of the WDR5 project’s development showcases the unique expertise of OICR DD, the advantages to the OICR-FACIT model, and how OICR effectively harnesses the strengths of Ontario’s diverse cancer research ecosystem by collaborating with groups such as the SGC.
Al-awar notes that drug discovery is always fraught with challenges – no matter the project. “However, by working together with our partners SGC and FACIT, we were able to overcome hurdles in both the scientific and business development of the WDR5 project,” she says. “Fusing discovery and commercialization at an early stage, as well as accessing FACIT’s critical seed-funding of Propellon, enabled us to accelerate along a clear path toward the clinic.”
“OICR and FACIT share a mission to translate advancements in cancer care for the benefit of patients, stakeholders and the Ontario economy,” says O’Neill. “With a focus on accelerating the development of a promising WDR5 inhibitor, FACIT continues to work toward selecting a partner that will provide the optimal clinical path for the technology. With patients in mind, we are excited by what the future holds for Propellon and cancer research translation in the province.”